Last reviewed · How we verify
Irbesartan SR47436
Irbesartan SR47436 is a Small molecule drug developed by Sanofi. It is currently FDA-approved. Also known as: Aprovel.
At a glance
| Generic name | Irbesartan SR47436 |
|---|---|
| Also known as | Aprovel |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy (NA)
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU. (PHASE3)
- ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) (PHASE2)
- Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy (NA)
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients (PHASE4)
- Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irbesartan SR47436 CI brief — competitive landscape report
- Irbesartan SR47436 updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Irbesartan SR47436
What is Irbesartan SR47436?
Irbesartan SR47436 is a Small molecule drug developed by Sanofi.
Who makes Irbesartan SR47436?
Irbesartan SR47436 is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).
Is Irbesartan SR47436 also known as anything else?
Irbesartan SR47436 is also known as Aprovel.
What development phase is Irbesartan SR47436 in?
Irbesartan SR47436 is FDA-approved (marketed).
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: Aprovel
- Compare: Irbesartan SR47436 vs similar drugs
- Pricing: Irbesartan SR47436 cost, discount & access